Boast­ing in-li­cense dis­tri­b­u­tion mod­el, Chi­nese EOC Phar­ma bags $32M se­ries B fund­ing for on­col­o­gy prod­ucts

With a new­ly pock­et­ed $32 mil­lion se­ries B, EOC Phar­ma is look­ing to bring po­ten­tial block­buster on­col­o­gy drugs to Chi­na — prod­ucts that it will have hand-picked, de­vel­oped, made and mar­ket­ed, all on the home turf.

The Shang­hai-based bio­phar­ma plans to use the funds to ad­vance its lead pro­grams in­to late-stage de­vel­op­ment in Chi­na with a fo­cus on reg­is­tra­tion stud­ies. This is a big step in the young com­pa­ny’s ef­forts to be­com­ing an “in­te­grat­ed” one-stop shop for de­vel­op­ment, man­u­fac­tur­ing and com­mer­cial­iza­tion, CEO Xi­aom­ing Zou told me.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER